Advertisement

Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis

  • Jennifer Y. Lee
  • Christopher J. Danford
  • Hirsh D. Trivedi
  • Elliot B. Tapper
  • Vilas R. Patwardhan
  • Alan BonderEmail author
Original Article

Abstract

Background and Aims

Fatigue is the most common complication of primary biliary cholangitis (PBC) and can be debilitating. Numerous interventions have been trialed targeting several proposed mechanisms of PBC-associated fatigue. We sought to summarize and perform a meta-analysis to determine the efficacy of these interventions.

Methods

A comprehensive database search was conducted from inception through March 27, 2018. The primary outcome was proportion of fatigued patients or reduction in degree of fatigue. Adverse events were a secondary outcome. We assessed studies for risk of bias, graded quality of evidence, and used meta-analysis to obtain overall effect by pooling studies of the same class.

Results

We identified 16 studies evaluating ursodeoxycholic acid (UDCA) (7), liver transplantation (2), serotonin reuptake inhibitors (2), colchicine (1), methotrexate (1), cyclosporine (1), modafinil (1), and obeticholic acid (1). On meta-analysis, UDCA was not associated with a reduction in risk of fatigue (RR = 0.86, 95% CI 0.69–1.08, p = 0.19, I2 = 56.2%). While liver transplantation did reduce degree of fatigue (SMD − 0.57, 95% CI − 0.89 to − 0.24, p = 0.001, I2 = 67.3%), fatigue did not return to baseline indicating the underlying cause may not be addressed.

Conclusions

While there is some improvement in fatigue with liver transplantation, there is a lack of high-quality evidence supporting the efficacy of any other intervention in the treatment of PBC-related fatigue. Further research into the underlying pathophysiology may help guide future trials.

Keywords

Primary biliary cirrhosis Liver transplantation Ursodeoxycholic acid Weakness Malaise 

Notes

Compliance with ethical standards

Conflict of interest

No outside funding or grant support was involved in the production of this manuscript. The authors have no pertinent conflicts of interest.

Supplementary material

10620_2019_5457_MOESM1_ESM.docx (46 kb)
Supplementary material 1 (DOCX 45 kb)

References

  1. 1.
    Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–1188.  https://doi.org/10.1016/j.jhep.2011.10.025.CrossRefPubMedGoogle Scholar
  2. 2.
    Witt-Sullivan H, Heathcote J, Cauch K, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology. 1990;12:98–105.CrossRefGoogle Scholar
  3. 3.
    Goldblatt J, Taylor PJS, Lipman T, et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology. 2002;122:1235–1241.  https://doi.org/10.1053/gast.2002.32993.CrossRefPubMedGoogle Scholar
  4. 4.
    Poupon RE, Chrétien Y, Chazouillères O, Poupon R, Chwalow J. Quality of life in patients with primary biliary cirrhosis. Hepatology. 2014;40:489–494.  https://doi.org/10.1002/hep.20276.CrossRefGoogle Scholar
  5. 5.
    Mells GF, Pells G, Newton JL, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58:273–283.  https://doi.org/10.1002/hep.26365.CrossRefPubMedGoogle Scholar
  6. 6.
    Al-Harthy N, Kumagi T, Coltescu C, Hirschfield GM. The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology. 2010;52:562–570.  https://doi.org/10.1002/hep.23683.CrossRefPubMedGoogle Scholar
  7. 7.
    Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology. 2006;44:91–98.  https://doi.org/10.1002/hep.21230.CrossRefPubMedGoogle Scholar
  8. 8.
    Selmi C, Gershwin ME, Lindor KD, et al. Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology. 2007;46:1836–1843.  https://doi.org/10.1002/hep.21953.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Jones DEJ, Bhala N, Burt J, Goldblatt J, Prince M, Newton JL. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut. 2006;55:536–541.  https://doi.org/10.1136/gut.2005.080317.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Jones DE, Al-Rifai A, Frith J, Patanwala I, Newton JL. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol. 2010;53:911–917.  https://doi.org/10.1016/j.jhep.2010.05.026.CrossRefPubMedGoogle Scholar
  11. 11.
    Jopson L, Jones DEJ. Fatigue in primary biliary cirrhosis: prevalence, pathogenesis and management. Dig Dis. 2015;33:109–114.  https://doi.org/10.1159/000440757.CrossRefPubMedGoogle Scholar
  12. 12.
    Jopson L, Hegade V, Mells G, Sandford R, Jones DE. P1197: natural history of fatigue and pruritus in primary biliary cirrhosis: implications for the role of pruritus in the aetiology and treatment of fatigue. J Hepatol. 2015;62:S804–S805.  https://doi.org/10.1016/S0168-8278(15)31393-3.CrossRefGoogle Scholar
  13. 13.
    Griffiths L, Jones DE. Pathogenesis of primary biliary cirrhosis and its fatigue. Dig Dis. 2014;32:615–625.  https://doi.org/10.1159/000360515.CrossRefPubMedGoogle Scholar
  14. 14.
    Stanca CM, Bach N, Krause C, et al. Evaluation of fatigue in U.S. patients with primary biliary cirrhosis. Am J Gastroenterol. 2005;100:1104–1109.  https://doi.org/10.1111/j.1572-0241.2005.41315.x.CrossRefPubMedGoogle Scholar
  15. 15.
    Jacoby A, Rannard A, Buck D, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54:1622–1629.  https://doi.org/10.1136/gut.2005.065862.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 2011. http://handbook.cochrane.org.
  17. 17.
    Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed October 6, 2018.
  18. 18.
    Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence–study limitations (risk of bias). J Clin Epidemiol. 2011;64:407–415.  https://doi.org/10.1016/j.jclinepi.2010.07.017.CrossRefPubMedGoogle Scholar
  19. 19.
    Combes B, Carithers RL, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995;22:759–766.PubMedGoogle Scholar
  20. 20.
    Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284–1290.CrossRefGoogle Scholar
  21. 21.
    Vuoristo M, Färkkilä M, Karvonen AL, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology. 1995;108:1470–1478.CrossRefGoogle Scholar
  22. 22.
    Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991;324:1548–1554.  https://doi.org/10.1056/nejm199105303242204.CrossRefPubMedGoogle Scholar
  23. 23.
    Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994;19:1149–1156.CrossRefGoogle Scholar
  24. 24.
    Parés A, Caballería L, Rodés J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol. 2000;32:561–566.CrossRefGoogle Scholar
  25. 25.
    Chan CW, Gunsar F, Feudjo M, et al. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment Pharmacol Ther. 2005;21:217–226.  https://doi.org/10.1111/j.1365-2036.2005.02318.x.CrossRefPubMedGoogle Scholar
  26. 26.
    Carbone M, Bufton S, Monaco A, Griffiths L, Jones DE, Neuberger JM. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol. 2013;59:490–494.  https://doi.org/10.1016/j.jhep.2013.04.017.CrossRefPubMedGoogle Scholar
  27. 27.
    Pells G, Mells GF, Carbone M, et al. The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. J Hepatol. 2013;59:67–73.  https://doi.org/10.1016/j.jhep.2013.02.019.CrossRefPubMedGoogle Scholar
  28. 28.
    Talwalkar JA, Donlinger JJ, Gossard AA, et al. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci. 2006;51:1985–1991.  https://doi.org/10.1007/s10620-006-9397-5.CrossRefPubMedGoogle Scholar
  29. 29.
    ter Borg PCJ, van Os E, van den Broek WW, Hansen BE, van Buuren HR. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterol. 2004;4:13.  https://doi.org/10.1186/1471-230X-4-13.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    González-Koch A, Brahm J, Antezana C, Smok G, Cumsille MA. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol. 1997;27:143–149.CrossRefGoogle Scholar
  31. 31.
    Wiesner RH, Ludwig J, Lindor KD, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med. 1990;322:1419–1424.  https://doi.org/10.1056/NEJM199005173222003.CrossRefPubMedGoogle Scholar
  32. 32.
    Silveira MG, Gossard AA, Stahler AC, et al. A randomized, placebo-controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis. Am J Ther. 2017;24:e167–e176.  https://doi.org/10.1097/MJT.0000000000000387.CrossRefPubMedGoogle Scholar
  33. 33.
    Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.  https://doi.org/10.1056/NEJMoa1509840.CrossRefPubMedGoogle Scholar
  34. 34.
    Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666–674.  https://doi.org/10.1002/hep.21553.CrossRefPubMedGoogle Scholar
  35. 35.
    Hegade VS, Kendrick SFW, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389:1114–1123.  https://doi.org/10.1016/S0140-6736(17)30319-7.CrossRefPubMedGoogle Scholar
  36. 36.
    Theal JJ, Toosi MN, Girlan L, et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology. 2005;41:1305–1312.  https://doi.org/10.1002/hep.20698.CrossRefPubMedGoogle Scholar
  37. 37.
    Prince MI, Mitchison HC, Ashley D, et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial. Aliment Pharmacol Ther. 2003;17:137–143.CrossRefGoogle Scholar
  38. 38.
    Jones DEJ, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther. 2007;25:471–476.  https://doi.org/10.1111/j.1365-2036.2006.03223.x.CrossRefPubMedGoogle Scholar
  39. 39.
    Ian Gan S, de Jongh M, Kaplan MM. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci. 2009;54:2242–2246.  https://doi.org/10.1007/s10620-008-0613-3.CrossRefPubMedGoogle Scholar
  40. 40.
    Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC study group. N Engl J Med. 1994;330:1342–1347.  https://doi.org/10.1056/nejm199405123301903.CrossRefPubMedGoogle Scholar
  41. 41.
    Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006;130:715–720.  https://doi.org/10.1053/j.gastro.2005.12.029.CrossRefPubMedGoogle Scholar
  42. 42.
    Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue in primary biliary cirrhosis. Gut. 1998;43:705–710.CrossRefGoogle Scholar
  43. 43.
    Floreani A, Franceschet I, Cazzagon N. Primary biliary cirrhosis: overlaps with other autoimmune disorders. Semin Liver Dis. 2014;34:352–360.  https://doi.org/10.1055/s-0034-1383734.CrossRefPubMedGoogle Scholar
  44. 44.
    Overman CL, Kool MB, Da Silva JAP, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol. 2016;35:409–415.  https://doi.org/10.1007/s10067-015-3035-6.CrossRefPubMedGoogle Scholar
  45. 45.
    Hardy T, MacDonald C, Jones DEJ, Newton JL. A follow-up study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Liver Int. 2010;30:1551–1552.  https://doi.org/10.1111/j.1478-3231.2010.02288.x.CrossRefPubMedGoogle Scholar
  46. 46.
    Khanna A, Jopson L, Howel D, et al. Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial. Hepatology. 2018;.  https://doi.org/10.1002/hep.30099.CrossRefPubMedGoogle Scholar
  47. 47.
    Hollingsworth KG, Newton JL, Robinson L, Taylor R, Blamire AM, Jones DEJ. Loss of capacity to recover from acidosis in repeat exercise is strongly associated with fatigue in primary biliary cirrhosis. J Hepatol. 2010;53:155–161.  https://doi.org/10.1016/j.jhep.2010.02.022.CrossRefPubMedGoogle Scholar
  48. 48.
    Hollingsworth KG, Newton JL, Taylor R, et al. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin Gastroenterol Hepatol. 2008;6:1041–1048.  https://doi.org/10.1016/j.cgh.2008.04.013.CrossRefPubMedGoogle Scholar
  49. 49.
    Myers RP, Swain MG, Lee SS, Shaheen AAM, Burak KW. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol. 2013;108:933–941.  https://doi.org/10.1038/ajg.2013.51.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jennifer Y. Lee
    • 1
  • Christopher J. Danford
    • 2
  • Hirsh D. Trivedi
    • 2
  • Elliot B. Tapper
    • 4
  • Vilas R. Patwardhan
    • 3
  • Alan Bonder
    • 3
  1. 1.Department of MedicineBeth Israel Deaconess Medical CenterBostonUSA
  2. 2.Division of Gastroenterology and HepatologyBeth Israel Deaconess Medical CenterBostonUSA
  3. 3.Liver Center, Autoimmune and Cholestatic Liver Disease Program, Department of MedicineBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonUSA
  4. 4.Division of Gastroenterology and Hepatology, University HospitalUniversity of MichiganAnn ArborUSA

Personalised recommendations